Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CAO Patricia Carr Sells 2,142 Shares

Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Rating) CAO Patricia Carr sold 2,142 shares of the business’s stock in a transaction on Monday, August 15th. The shares were sold at an average price of $160.06, for a total value of $342,848.52. Following the completion of the sale, the chief accounting officer now owns 5,934 shares in the company, valued at $949,796.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Jazz Pharmaceuticals Trading Down 0.7 %

Shares of NASDAQ:JAZZ traded down $1.12 during trading hours on Wednesday, hitting $157.60. 592,959 shares of the company’s stock traded hands, compared to its average volume of 568,839. The company has a debt-to-equity ratio of 1.87, a current ratio of 3.67 and a quick ratio of 2.45. The firm has a market capitalization of $9.84 billion, a P/E ratio of -186.73, a price-to-earnings-growth ratio of 1.35 and a beta of 0.69. The business has a fifty day moving average price of $153.98 and a 200-day moving average price of $152.77. Jazz Pharmaceuticals plc has a 1 year low of $117.64 and a 1 year high of $169.98.

Analysts Set New Price Targets

JAZZ has been the topic of a number of analyst reports. Piper Sandler decreased their price objective on Jazz Pharmaceuticals from $197.00 to $193.00 in a research note on Thursday, May 5th. HC Wainwright cut their price objective on Jazz Pharmaceuticals from $210.00 to $204.00 in a report on Friday, August 5th. SVB Leerink increased their target price on Jazz Pharmaceuticals from $200.00 to $210.00 and gave the company an “outperform” rating in a report on Thursday, August 4th. UBS Group dropped their target price on Jazz Pharmaceuticals from $194.00 to $191.00 and set a “buy” rating for the company in a report on Thursday, August 4th. Finally, Cowen increased their price objective on Jazz Pharmaceuticals from $200.00 to $225.00 in a report on Thursday, May 5th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $203.69.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of large investors have recently bought and sold shares of JAZZ. Private Capital Group LLC increased its position in shares of Jazz Pharmaceuticals by 1,975.0% during the first quarter. Private Capital Group LLC now owns 166 shares of the specialty pharmaceutical company’s stock worth $26,000 after purchasing an additional 158 shares in the last quarter. Lloyd Advisory Services LLC. purchased a new stake in shares of Jazz Pharmaceuticals during the 1st quarter worth about $29,000. Quent Capital LLC purchased a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth about $31,000. Gladius Capital Management LP purchased a new position in Jazz Pharmaceuticals in the 2nd quarter valued at about $33,000. Finally, Elequin Capital LP purchased a new position in Jazz Pharmaceuticals in the 1st quarter valued at about $42,000. Institutional investors own 93.23% of the company’s stock.

Jazz Pharmaceuticals Company Profile

(Get Rating)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

Featured Articles

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.